All In Biotech

Drug Trial Radar · NCT07360314

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

A Phase 1, 2-Part, Multicenter, Open-Label, First-in-Human Study of the Anti-Ly6E Exatecan Antibody-Drug Conjugate M7437 in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Sep 28, 2028

Study completion Mar 28, 2029

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).

Conditions

  • Advanced Solid Tumors

Interventions

  • M7437Drug

    Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.

  • M7437Drug

    Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs)Time frame: DLT period is 21 days (cycle 1)
  2. Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs)Time frame: Up to end of Part 1 of study (approximately 1 year 8 months)

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Yale University - Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center

    Huntersville, North Carolina · Recruiting

  • NEXT Houston

    Galveston, Texas · Recruiting

  • NEXT Oncology - PARENT

    San Antonio, Texas · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Canada · Recruiting

  • BC Cancer - Vancouver - BC Cancer Agency

    Vancouver, Canada · Not yet recruiting

  • National Cancer Center Hospital

    Tokyo, Japan · Recruiting

  • Hospital Universitari Vall d'Hebron - VHIO - Oncology - Phase I Unit

    Barcelona, Spain · Not yet recruiting

  • NEXT Madrid - Hospital Universitario Quironsalud Madrid

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.